ArticleJACC. Case reports2026
Severe Aortic Stenosis and Acute Hip Fracture: An Expedited TAVR-First Pathway.
Article in JACC. Case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
clinical conditionAn elderly man presented with severe symptomatic aortic stenosis (AS) and an acute acetabular fracture, representing a high-risk intersection of cardiovascular and orthopedic emergencies. KEY QUESTIONS: What are the mechanistic and clinical links between AS and hip fracture (HFx)? How should management balance the urgency of fracture fixation with the hemodynamic instability of severe AS? What are the logistical and procedural considerations for performing transcatheter aortic valve replacement (TAVR) in this setting? What antithrombotic strategy should guide periprocedural management? Which complications can be avoided with a structured, multidisciplinary pathway? OUTCOME: The patient underwent expedited, minimalist transfemoral TAVR under conscious sedation on day 1, followed by HFx repair on day 2. He recovered without complications, was discharged on day 4, and remained fully independent at 1 year with stable valve function and no paravalvular leak. TAKE-HOME MESSAGES: In carefully selected patients with severe AS and acute HFx managed at TAVR-capable centers, a coordinated, expedited TAVR-first strategy appears feasible and may enable safe, timely orthopedic repair and recovery. Antithrombotic management must be individualized. Multidisciplinary, time-sensitive management is essential, and patient selection remains paramount.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.